Angi Inc
F:2UH
Decide a qué precio te sentirías cómodo comprando y te ayudaremos a estar preparado.
|
A
|
Angi Inc
F:2UH
|
US |
|
Tenax Therapeutics Inc
NASDAQ:TENX
|
US |
|
M
|
Metro AG
DUS:B4B3
|
DE |
|
D'Ieteren Group NV
LSE:0ON7
|
BE |
|
P
|
Peninsula Energy Ltd
XBER:P1M
|
AU |
|
C
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
US |
|
Bumi Resources Minerals Tbk PT
IDX:BRMS
|
ID |
|
Delta Plus Group SA
F:7E1
|
FR |
|
Newcrest Mining Ltd
ASX:NCM
|
AU |
|
P
|
PureTech Health PLC
NASDAQ:PRTC
|
US |
|
C
|
Capital Power Corp
XBER:2CP
|
CA |
|
Moschip Technologies Ltd
NSE:MOSCHIP
|
IN |
|
Mayora Indah Tbk PT
F:D7V
|
ID |
|
F
|
Fresenius SE & Co KGaA
OTC:FSNUY
|
DE |
|
TSS Inc
OTC:TSSI
|
US |
|
Banco do Brasil SA
OTC:BDORY
|
BR |
|
G
|
Graincorp Ltd
XMUN:G3C
|
AU |
|
Canara Bank Ltd
BSE:532483
|
IN |
|
A
|
Astera Labs Inc
NASDAQ:ALAB
|
US |
|
WEG SA
BOVESPA:WEGE3
|
BR |
|
GlobalData PLC
LSE:DATA
|
UK |
|
B
|
Bri-Chem Corp
OTC:BRYFF
|
CA |
|
C
|
Curtiss-Wright Corp
F:CWT
|
US |
|
UIE PLC
F:I55
|
MT |
Reverse DCF
To justify the current price, Netflix Inc. must grow revenue by 36% annually over the next 5 years, which is outside the range of what's considered realistic.
| Revenue Growth Rate | DCF Value | |
|---|---|---|
|
Realistic Range
|
Realistic Low: 10%
|
$601.26
Overvalued by 45%
|
|
Historical: 21%
|
$758.26
Overvalued by 36%
|
|
|
Current DCF: 23%
|
$789.44
Overvalued by 32%
|
|
|
Wall Street: 24%
|
$831.32
Overvalued by 28%
|
|
|
Realistic High: 30%
|
$900.12
Overvalued by 12%
|
|
|
Implied by Price: 36%
|
$977.59
Matches Stock Price
|